Steve Krognes compensation by year
Denali Therapeutics Summary Compensation Table · all 6 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Salary | $437,750 | $455,260 | $470,057 | $484,200 | $501,150 | $167,067 |
| Bonus | $218,875 | $393,682 | $188,023 | $387,362 | $300,690 | $0 |
| Stock awards | $0 | $179,673 | $305,830 | $1,364,638 | $2,125,800 | $1,465,370 |
| Option awards | $497,350 | $2,948,616 | $1,558,941 | $2,018,444 | $3,648,420 | $2,647,757 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $12,585 | $24,000 | $7,834 | $11,400 | $11,600 | $6,683 |
| Total | $1,166,560 | $4,001,231 | $2,530,685 | $4,266,044 | $6,587,660 | $4,286,877 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Denali Therapeutics Inc. DEF 14A filed April 18, 2023, accession 0001714899-23-000062, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Denali Therapeutics Inc. filed document, accession 0001714899-23-000062. Every figure is read from that document and cited to the page and table it appears in. Filed April 18, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 22,500 | $625,725 | — |
| RSU | 14,572 | $405,247 | — |
| RSU | 10,000 | $278,100 | — |
| RSU | 4,250 | $118,193 | — |
| Option | 39,668 | — | $24.81 |
| Option | 46,876 | — | $70.86 |
| Option | 5,669 | — | $17.99 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Denali Therapeutics Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
19 Form 4 lines since the FY2022 proxy (filed April 18, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-03 | Grant or award | — | 6,408 | $0.00 | 38,202 |
| 2026-06-03 | Grant or award derivative | — | 19,226 | $0.00 | 19,226 |
| 2025-06-03 | Grant or award | — | 6,037 | $0.00 | 31,794 |
| 2025-06-03 | Grant or award derivative | — | 18,111 | $0.00 | 18,111 |
| 2025-01-07 | Sale | — | 3,339 | $20.81 | 25,757 |
| 2024-12-31 | Sale | 10b5-1 | 30,000 | $20.25 | 29,096 |
| 2024-09-30 | Sale | 10b5-1 | 30,000 | $29.03 | 29,096 |
| 2024-08-20 | Sale | — | 1,727 | $23.79 | 32,677 |
The 8 most recent of 19 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Denali Therapeutics’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Ryan Watts | President and Chief Executive Officer | $9,284,688 |
| Carole Ho | Chief Medical Officer | $5,692,052 |
| Alexander Schuth | Chief Operating and Financial Officer and Secretary | $5,692,052 |
| Steve Krognes · this page | Chief Financial Officer and Treasurer (until May 1, 2022) | $4,286,877 |
Board service
Denali Therapeutics board · FY2022–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $55,769 | $84,095 | $157,285 | $0 | $297,149 |
| FY2024 | $45,000 | $110,748 | $203,717 | — | $359,465 |
| FY2023 | $45,000 | $130,359 | $244,075 | — | $419,434 |
| FY2022 | $30,021 | $0 | $0 | — | $30,021 |
Each year as the company reported it in Denali Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Denali Therapeutics pays directors a $50,000 cash retainer. As stated in Denali Therapeutics's FY2025 proxy.
Committees
Audit
The full Denali Therapeutics compensation record
free company briefThis page is one person within Denali Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Denali Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Denali Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.